A new blood test, called Stockholm3, is showing promise in clinical trials for detecting high-risk prostate cancer cases earlier. The test, which estimates a man’s risk of aggressive prostate cancer, detected 90% of aggressive prostate cancer cases compared to 74% for traditional prostate-specific antigen (PSA) tests.
Study Findings
In a study published in the Annals of Internal Medicine, researchers from the Karolinska Institutet in Sweden studied the test’s efficacy in more than 12,000 men. The study found that Stockholm3 identified significantly more aggressive cancer cases than PSA, without increasing the number of unnecessary follow-ups.
According to the study, when aggressive prostate cancer is found while still confined in the prostate, the five-year survival rate is close to 100%, highlighting the importance of early detection. The test could reduce the need for unnecessary MRIs and biopsies.
Original reporting: Fox News (HLL/CB) — read the source article.
